Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | VNN1 | O95497 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970291 | 0.92 | CES2 (0.61) | DDR1CES2LMNAMEN1KMT2A | |
| SCHEMBL423797 | 0.90 | MEN1 (0.62) | DDR1CES2LMNAMEN1KMT2A | |
| SCHEMBL17581950 | 0.88 | CES2 (0.56) | DDR1CES2LMNAMEN1KMT2A | |
| SCHEMBL11503483 | 0.86 | DDR1 (0.59) | DDR1CES2LMNAMAPTCYP26A1 | |
| SCHEMBL4749524 | 0.86 | CES2 (0.54) | DDR1CES2MEN1KMT2AMAPT | |
| SCHEMBL3282343 | 0.86 | CES2 (0.54) | DDR1CES2LMNAMEN1KMT2A | |
| SCHEMBL2929610 | 0.86 | VNN1 (0.57) | DDR1CES2MEN1KMT2ASRD5A2 | |
| SCHEMBL27952195 | 0.84 | CES2 (0.56) | CES2LMNAMEN1KMT2AMAPT | |
| SCHEMBL28882273 | 0.83 | CES2 (0.62) | CES2LMNAMEN1KMT2AMAPT | |
| SCHEMBL9602346 | 0.83 | VNN1 (0.61) | DDR1CES2MEN1KMT2AVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468708-B1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | COGNIS IP MAN GMBH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2468708-A1 | Catalytic decarboxylative cross-ketonisation of aryl- and alkylcarboxylic acids using iron catalysts | Cognis IP Management GmbH (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| US-6380436-B1 | REACTING 4-TRIFLUOROMETHYLBENZONITRILE WITH GRIGNARD REAGENT | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | DDR1 2340/4885CES2 653/4885LMNA 2615/4885 |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | DDR1 497/4885CES2 4307/4885LMNA 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.